LAUREL, MD and SASKATOON, SK--(MARKET WIRE)--Aug 6, 2007 -- BioServe and Phenomenome Discoveries Inc. (“PDI”) today announced that they have developed a novel serum-based diagnostic test for the identification of colorectal cancer (CRC), and pre-cancerous states conducive to the development of CRC. Colorectal cancer comprises a tenth of the global cancer burden, and is the third most common malignancy in the world. According to the National Cancer Institute, in the United States during 2007 there were an estimated 153,760 new cases of colorectal cancer and 52,180 deaths from the disease.
